$COPR
Idaho Copper Corp

2022 Q3 Form 10-Q Financial Statement

#000121390022046308 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $10.02K $30.30K $14.35K
YoY Change -7.9% 130.77% -65.66%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.02K $30.30K $14.35K
YoY Change -7.9% 130.7% -65.66%
Operating Profit -$10.02K -$30.30K -$14.35K
YoY Change -7.9% 130.7% -65.66%
Interest Expense $92.93K $102.4K
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$10.02K -$30.30K -$14.35K
YoY Change -7.9% 130.7% -65.66%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.02K -$30.30K -$14.35K
YoY Change -7.9% 130.7% -99.1%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$499.70 -$715.60
COMMON SHARES
Basic Shares Outstanding 20.05M shares 20.05M shares
Diluted Shares Outstanding 20.05M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.134M $1.134M
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $153.7K $143.7K $107.1K
YoY Change 65.78% 75.61% -87.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $153.7K $143.7K $107.1K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $153.7K $143.7K $107.1K
YoY Change 65.79% 75.6% -87.61%
SHAREHOLDERS EQUITY
Retained Earnings -$7.407M -$7.397M -$7.356M
YoY Change
Common Stock $20.05K $20.05K $20.05K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$153.7K -$143.7K -$107.1K
YoY Change
Total Liabilities & Shareholders Equity
YoY Change

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income -$10.02K -$30.30K -$14.35K
YoY Change -7.9% 130.7% -99.1%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $0.00 $0.00 -$1.390K
YoY Change -100.0% -100.0% -98.99%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $119.1K
YoY Change
Cash From Investing Activities $0.00 $0.00 $119.1K
YoY Change -249.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -117.7K
YoY Change -100.0% -100.0% -168.32%
NET CHANGE
Cash From Operating Activities 0.000 0.000 -1.390K
Cash From Investing Activities 0.000 0.000 119.1K
Cash From Financing Activities 0.000 0.000 -117.7K
Net Change In Cash 0.000 0.000 -0.000000000002046
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities $0.00 $0.00 -$1.390K
Capital Expenditures $0.00
Free Cash Flow -$1.390K
YoY Change -97.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20054000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20054000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20054000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20054000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
20054 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20054 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-108715
dei Entity Registrant Name
EntityRegistrantName
Joway Health Industries Group Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0221494
dei Entity Address Address Line1
EntityAddressAddressLine1
600 South
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89101
dei City Area Code
CityAreaCode
(702)
dei Local Phone Number
LocalPhoneNumber
384-1990
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20054000 shares
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
143682 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
103053 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3999 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
143682 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
107052 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7232861 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7228862 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7396597 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7355968 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-143682 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-107052 usd
CY2022Q2 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-30295 usd
CY2021Q2 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-13132 usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-40629 usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-96557 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
30295 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
13132 usd
us-gaap Operating Expenses
OperatingExpenses
40629 usd
us-gaap Operating Expenses
OperatingExpenses
96557 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30295 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13132 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-40629 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-96557 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30295 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13132 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40629 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96557 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30295 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13132 usd
us-gaap Net Income Loss
NetIncomeLoss
-40629 usd
us-gaap Net Income Loss
NetIncomeLoss
-96557 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30295 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13132 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40629 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96557 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20054000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20054000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20054000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20054000 shares
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-40629 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-96557 usd
gtvi Receivable From Disposal Of Subsidiaries
ReceivableFromDisposalOfSubsidiaries
119070 usd
gtvi Increase Decrease In Special Dividend Payables
IncreaseDecreaseInSpecialDividendPayables
119070 usd
gtvi Increase Decrease In Other Payable
IncreaseDecreaseInOtherPayable
40629 usd
gtvi Increase Decrease In Other Payable
IncreaseDecreaseInOtherPayable
29560 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66997 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
66997 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66997 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
119070 usd
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
10000 shares
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
119070 usd
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.45
CY2021Q1 us-gaap Shares Issued
SharesIssued
17408000 shares
gtvi Incurred Net Losses
IncurredNetLosses
40629 usd
gtvi Incurred Net Losses
IncurredNetLosses
96557 usd
CY2022Q2 gtvi Accumulated Deficit
AccumulatedDeficit
7400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2 gtvi Loss From Disposal Of Discontinued Component Gross
LossFromDisposalOfDiscontinuedComponentGross
2243225 usd
CY2022Q2 gtvi Loss From Disposal Of Discontinued Component Net Of Income Tax
LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax
-1340795 usd
gtvi Shareholder Holding Percentage
ShareholderHoldingPercentage
0.8681 pure
CY2022Q2 gtvi Cash Consideration Per Share
CashConsiderationPerShare
0.045
CY2020Q4 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
20054000 shares
us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
1340795 usd
CY2021Q1 gtvi Cash Received
CashReceived
119070 usd
CY2021Q1 gtvi Payment Per Share
PaymentPerShare
0.045
CY2021Q1 gtvi Offset Shares
OffsetShares
17408000 shares
CY2022Q2 gtvi Selling Price
SellingPrice
902430 usd
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
79446 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1133812 usd
CY2022Q2 us-gaap Deferred Tax Liabilities Regulatory Assets
DeferredTaxLiabilitiesRegulatoryAssets
3194533 usd
CY2022Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
465007 usd
CY2022Q2 us-gaap Other Liabilities
OtherLiabilities
1977822 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax
AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
-651751 usd
CY2022Q2 us-gaap Dividend Payments Restrictions Schedule Statutory Capital And Surplus1
DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1
143682 usd
CY2021Q4 us-gaap Dividend Payments Restrictions Schedule Statutory Capital And Surplus1
DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1
103053 usd
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
3999 usd
CY2022Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001263364

Files In Submission

Name View Source Status
0001213900-22-046308-index-headers.html Edgar Link pending
0001213900-22-046308-index.html Edgar Link pending
0001213900-22-046308.txt Edgar Link pending
0001213900-22-046308-xbrl.zip Edgar Link pending
f10q0622ex31-1_jowayhealth.htm Edgar Link pending
f10q0622ex32-1_jowayhealth.htm Edgar Link pending
f10q0622_jowayhealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
f10q0622_jowayhealth_htm.xml Edgar Link completed
gtvi-20220630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gtvi-20220630_lab.xml Edgar Link unprocessable
gtvi-20220630_pre.xml Edgar Link unprocessable
gtvi-20220630_cal.xml Edgar Link unprocessable
gtvi-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable